Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 94Prostatic Neoplasms, Castration-Resistant 10Neoplasm Metastasis 8Breast Neoplasms 8Neoplasms 7Triple Negative Breast Neoplasms 4Metastatic Castration-Resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Bulbo-Spinal Atrophy, X-Linked 3Adenocarcinoma 3mCRPC 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostate Adenocarcinoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Bites and Stings 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1

Interventions

enzalutamide 2Docetaxel 2Androgen Antagonists 2darolutamide 1apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer × enzalutamide × 1 year × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡